NCT01096511已完成不适用
Clinical Effectiveness and Safety Study of Moxifloxacin i.v. in the Treatment of Complicated Intra-Abdominal Infection (cIAI)
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 1,001
- 主要终点
- Types of cIAI infections
研究概览
简要总结
This study is a local, prospective, open-label, company-sponsored, non interventional, multi-center study. Patients documented must suffer from a cIAI and take at least one dose of Moxifloxacin infusion.The primary objective is to define the types of cIAI infections that require Moxifloxacin i.v. therapy in China.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients at least 18 years of age with a diagnosis of cIAI treated with Moxifloxacin infusion with/without sequential tablet treatment can be included into the study. The local Moxifloxacin product information must be considered.
排除标准
- •Contraindications stated in the local Moxifloxacin product information. Warnings and precautions, stated in the local Moxifloxacin product information must be considered as potential exclusion criteria.
研究组 & 干预措施
Group 1
干预措施: Moxifloxacin (Avelox, BAY12-8039) (Drug)
结局指标
主要结局
Types of cIAI infections
时间窗: Day 1
次要结局
- Cure rate(5-14 days)
- Adverse event collection(5-14 days)
- Clinical signs and symptoms(5-14 days)
- Duration until improvement and cure(5-14 days)
研究者
相似试验
已完成
3 期
Dragon Study (the Safety and Efficacy for Treatment of Patients With Complicated Intra Abdominal Infections)Infection, Intra-abdominalNCT00769171Bayer364
已完成
3 期
BAY12-8039, iv/Oral Pulmonary Abscess/Aspiration PneumoniaPneumonia, AspirationLung AbscessNCT01045902Bayer139
已完成
3 期
A Study to Assess the Efficacy and Safety of IV/PO Moxifloxacin in Subjects With Community-acquired PneumoniaPneumoniaNCT00717561Bayer60
已完成
3 期
Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal InfectionIntraabdominal InfectionsNCT01069900Bayer458
已完成
3 期
A Study to Assess Efficacy and Safety of IV/PO Moxifloxacin in the Treatment of cSSSIsInfectious DiseasesNCT00828971Bayer16